Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Tuesday 12 March, 2019

Renalytix AI PLC

Investor briefing

RNS Number : 5235S
Renalytix AI PLC
12 March 2019
 

Renalytix AI plc

("RenalytixAI" or the "Company")

 

Investor briefing

Seminar focused on AI-enabled diagnostics for kidney disease

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces that it will host investor briefings focused on AI-enabled diagnostics and kidney disease on Monday 25 March 2019.

 

A welcome and introduction will be given by James McCullough and Julian Baines, CEO and Chairman respectively. The seminars will also feature the below speakers:

 

·     Steven Coca, MD - Co-founder RenalytixAI, Associate Professor, Medicine, Nephrology; Associate Chair for Clinical and Translational Research, Icahn School of Medicine at Mount Sinai

·     Fergus Fleming, PhD - Chief Technical Officer RenalytixAI

·     Rahul Patel - Executive Vice President Healthcare & Lifesciences, Persistent Systems

·     Erik Lium, PhD - EVP Mount Sinai Innovation Partners, Assistant Vice Chancellor of Innovation, Technology & Alliances at UCSF

 

A morning seminar will welcome Institutional Investors with the afternoon seminar open to High Net Worth Individuals and Retail Investors. The same discussion topics and Q&A session will be available at each meeting.

 

Invitations will be sent out shortly, by the Company's brokers, for the morning seminar.

 

The afternoon seminar will take place at the Brand Exchange, 3 Birchin Lane, EC3V 9BW at 4.45pm for a 5.00pm start. This will be followed by light refreshments and a chance to network with all members of the Company's management team in attendance.

 

If you would like to register to attend the afternoon briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected] 

 

No new material information will be disclosed during the event.

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

 



Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)

Peter Lees (Corporate Broking)




N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas  (Corporate Finance)
Tom Salvesen
/ Mia Gardner   (Corporate Broking)

 


 

 

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

 

 

 

 

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant and an estimated $114 billion is spent annually treating chronic kidney disease in the US.

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRASFEEFFFUSEID

a d v e r t i s e m e n t